918博天堂(中国)

    Eribulin

    HALAVEN®

    About HALAVEN®

    1. Marketed by Eisai Inc.
    2. Microtubule dynamics inhibitor
    3. Treatment of refractory, metastatic breast cancer and liposarcoma

    Approvals

    1. First U.S. approval: November 15, 2010
    2. First E.U. approval: March 17, 2011

    Constraint date forecast:

    1. Patent expiry: 2023 (United States)
    2. SPC expiry: 2024 (European Union)
    3. Patent expiry: 2024 (Japan)

    API availability

    Source: Cortellis Generics Intelligence

    The future of the generics landscape

    From innovation to bottom line

    Access our global intelligence, advanced analytics and global team of experts.

    Contact our team